Isis Pharmaceuticals (ISIS) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed Dec 24, 8:56AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "dead cat bounce" (down big yesterday but up big today) candidate
ISIS: 59.49 (+1.88)
Jim Cramer's Picks for What to Buy in Oil and Biotech Into 2015
at The Street - Wed Dec 24, 7:45AM CST
Here's the best way to play oil and biotech.
CI: 104.23 (-0.08), ESRX: 85.48 (-0.40), RDS.A: 68.42 (-0.31), ISIS: 59.49 (+1.88), COG: 30.21 (-0.39), UNH: 102.68 (-0.17), EOG: 94.05 (-2.36), SLB: 87.06 (-0.26), EPD: 35.45 (+0.25), CELG: 109.60 (+3.48)
After Yesterday's Decline of 8.38%, Isis Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 4:01PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $55.65 to a high of $62.14. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $57.95 on volume of 6.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 59.49 (+1.88)
Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
MCBK: 20.30 (+1.04), ISIS: 59.49 (+1.88), ALNY: 93.52 (+0.97), GILD: 91.29 (+1.84), ASPS: 33.81 (+4.37), ACHN: 13.06 (+1.22), OFLX: 34.45 (unch), RCPT: 122.05 (+4.05), HGSH: 4.60 (-0.06), REXX: 5.17 (-0.17)
Isis Pharmaceuticals Up 84.2% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Tue Dec 23, 9:37AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 5 months, Isis Pharmaceuticals has returned 84.21% as of today's recent price of $61.02.
ISIS: 59.49 (+1.88)
Isis Pharmaceuticals (ISIS) Stock: Weak On High Volume Today
at The Street - Tue Dec 23, 9:04AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a weak on high relative volume candidate
ISIS: 59.49 (+1.88)
3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
Watch for Isis Pharmaceuticals to Potentially Pullback After Gaining 9.30% Yesterday
Comtex SmarTrend(R) - Fri Dec 19, 3:36PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $60.85 to a high of $67.12. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $60.04 on volume of 9.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 59.49 (+1.88)
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half
at The Street - Fri Dec 19, 9:46AM CST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GILD: 91.29 (+1.84), IMGN: 5.90 (+0.13), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST
KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)
Why Isis Pharmaceuticals (ISIS) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:00AM CST
Isis Pharmaceuticals has been witnessing a positive trend in its current quarter earnings estimate and possess a favorable Zacks Industry Rank
ISIS: 59.49 (+1.88)
Jim Cramer's Top Stock Picks: BA MMM ISIS Q
at The Street - Fri Dec 19, 5:00AM CST
Cramer says Isis Pharmaceuticals is the next hot biotech and he's a big fan of drug testing provider Quintiles.
MMM: 166.96 (+0.09), Q: 59.48 (+0.01), ISIS: 59.49 (+1.88), BA: 131.24 (+1.21)
Cramer's Mad Money - Which Biotech Is The Next Regeneron? (12/18/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Dec 19, 4:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday December 18. Recipe For a Rally: Rite Aid (NYSE: RAD ), Kraft (NASDAQ: KRFT ), Accenture (NYSE: ACN ), Darden (NYSE: DRI ), Boeing (NYSE: BA ), 3M (NYSE:...
MMM: 166.96 (+0.09), ISIS: 59.49 (+1.88), Q: 59.48 (+0.01), JBL: 21.88 (+0.17), WYNN: 150.90 (-0.79), KRFT: 63.90 (-0.11), MGM: 20.77 (-0.17), BA: 131.24 (+1.21), ACN: 91.32 (-0.10), REGN: 400.12 (+6.07), DRI: 58.42 (-0.09), RAD: 7.26 (-0.09)
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally
at The Street - Thu Dec 18, 7:10PM CST
Cramer lists 10 ingredients in this seasonally strong market that will lead to a rally.
WFM: 48.67 (-0.40), MMM: 166.96 (+0.09), WMT: 86.43 (-0.23), HSBC: 47.71 (+0.18), M: 64.26 (+0.22), BA: 131.24 (+1.21), CELG: 109.60 (+3.48), SBUX: 81.27 (-0.16), RIG: 18.77 (-0.37), ISIS: 59.49 (+1.88), JPM: 62.48 (unch), Q: 59.48 (+0.01), GILD: 91.29 (+1.84), KBR: 17.00 (-0.13), FLR: 60.30 (-0.26), COST: 143.65 (-0.50), REGN: 400.12 (+6.07)
Uptrend Call Working As Isis Pharmaceuticals Stock Rises 66.0% (ISIS)
Comtex SmarTrend(R) - Tue Dec 16, 9:07AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 months, Isis Pharmaceuticals has returned 65.97% as of today's recent price of $54.98.
ISIS: 59.49 (+1.88)
Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
PR Newswire - Tue Dec 16, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA.
ISIS: 59.49 (+1.88)
Trade-Ideas: Isis Pharmaceuticals (ISIS) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Mon Dec 15, 10:41AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ISIS: 59.49 (+1.88)
Cramer's Mad Money - 13 Things To Watch In The Week Ahead (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 12. 13 Things to Watch in the Week Ahead: Honeywell (NYSE: HON ), Verifone (NYSE: PAY ), Darden (NYSE: DRI ), 3M (NYSE: MMM ), FedEX (NYSE: FDX ),...
JOY: 48.23 (+0.31), FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), LBRDA: 50.88 (-0.37), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), BBRY: 10.67 (-0.13), CHTR: 167.46 (-0.31), XON: 26.19 (+0.67), RMTI: 8.41 (-0.07), ORCL: 46.23 (+0.22), DRI: 58.42 (-0.09), KMX: 67.61 (-0.15), PAYX: 47.06 (-0.31), ISIS: 59.49 (+1.88), RHT: 70.92 (+0.47), JDSU: 14.01 (+0.13), AGIO: 109.67 (+2.45), FL: 55.31 (+0.09), PAY: 37.55 (-0.83), REGN: 400.12 (+6.07), PII: 150.40 (+0.38)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.35 (+0.21), ISIS: 59.49 (+1.88), GLYC: 7.81 (-0.42), RGDO: 0.89 (unch)
Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 88.76 (+3.23), RH: 96.97 (-0.16), ISIS: 59.49 (+1.88), COST: 143.65 (-0.50), AGIO: 109.67 (+2.45)